TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8465834
Drug: Average on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average on-treatment DBP < 95 mm Hg in MRFIT
Study: 26220816
Drug: Personal digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal digital assistant (e.g., iPod Touch)
Study: 23017329
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg/45 kg)
Study: 12771298
Drug: Calcijex injected
Normalized name: Calcijex Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcijex injected directly into the PTG (2 microg/ml preparation)
Study: 12771298
Drug: Calcijex injected
Normalized name: Calcijex Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcijex injected directly into the PTG (1 microg/ml preparation)
Study: 8427339
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (20 g)
Study: 3296854
Drug: Standard anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anesthetic and analgesic techniques without EAA
Study: 30949742
Drug: B.T. Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: B.T. Enema (sodium dihydrogen phosphate + disodium hydrogen phosphate) 135 ml
Study: 27190094
Drug: DREAMS 2G
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DREAMS 2G drug-eluting absorbable metal scaffold
Study: 19307994
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oregovomab infusion on the same day as chemotherapy (SIM)
Study: 19307994
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oregovomab infusion 1 week after chemotherapy (OWD)
Study: 19307994
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oregovomab infusion (both SIM and OWD)
Study: 19307994
Drug: Front-line chemotherapy
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-line chemotherapy with carboplatin-paclitaxel
Study: 19307994
Drug: Front-line chemotherapy
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-line chemotherapy with carboplatin-paclitaxel combined with oregovomab
Study: 16391383
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of nitroprusside
Study: 16391383
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of adenosine
Study: 16391383
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of verapamil
Study: 16391383
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of nitroglycerin (control group)
Study: 10647318
Drug: Control programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control programs (shorter outpatient programs or no treatment)
Study: 9302302
Drug: Percutaneous drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous drainage with albendazole (10 mg/kg/day for 8 weeks)
Study: 8331011
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (r‐HuEPO) at a dose of 200 units/kg/day, five times a week with iron supplements (Fe SO4, 325 mg. p.o., t.i.d.)
Study: 3304952
Drug: Cyclandelate (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (3.2 g daily in 2 doses)
Study: 3304952
Drug: Cyclandelate with
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate with concomitant cholestyramine (16 g daily)
Study: 3304952
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with concomitant cholestyramine (16 g daily)
Study: 22889084
Drug: Platform-switching implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switching implants (58 implants restored with medialised abutments)
Study: 22889084
Drug: Standard platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard platform implants (56 implants restored with standard matching-diameter abutments)
Study: 15752888
Drug: RT/CCT (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT/CCT (70 to 72.5 Gy accelerated hyperfractionated RT at 1.25 Gy b.i.d. with 2 cycles of CDDP (12‐20 mg/m(2)/d x 5 days) and continuous infusion 5‐FU (600 mg/m(2)/d x 5 days) during Week 1 and Week 6)
Study: 11890430
Drug: Chiropractic technique,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic technique, lumbar spine flexion‐distraction, combined with manual Trigger Point Therapy
Study: 7653696
Drug: Sertraline (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-200 mg/day, flexible dosing)
Study: 2672480
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with fluorouracil (5‐FU) (400 mg/m2 i.v., days 1‐5) and lomustine (CCNU) (100 mg/m2 per os on day 5) every 6 weeks for 9 cycles
Study: 2672480
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (surgery alone)
Study: 2672480
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with fluorouracil (5‐FU) and lomustine (CCNU)
Study: 55646
Drug: Intrapleural B.C.G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural B.C.G.
Study: 55646
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no B.C.G. treatment)
Study: 26957290
Drug: Paracetamol 325
Normalized name: Paracetamol 325 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 325 mg/tramadol 37.5 mg
Study: 18330060
Drug: L-glutamine ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine ORS
Study: 15893170
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg folic acid
Study: 10608624
Drug: PRP‐T (Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP‐T (Hib conjugate vaccine combined with DTP)
Study: 1750637
Drug: Caudal blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal blockade with bupivacaine 20 ml 0.5%
Study: 6785799
Drug: Carbamazepine (200-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (200-600 mg for 1 year)
Study: 20850365
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d) + calcium (500 mg/d) (n=23)
Study: 20850365
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + calcium (500 mg/d) (n=23)
Study: 20850365
Drug: Any raloxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any raloxifene treatment
Study: 2693405
Drug: Nimodipine 40
Normalized name: nimodipine 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 40 mg t.i.d.
Study: 703670
Drug: (+)-Cyanidanol-3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-Cyanidanol-3 at a dosage of 6 tablets per day (3000 mg per day)
Study: 703670
Drug: (+)-Cyanidanol-3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-Cyanidanol-3 at a dosage of 3 X 1 tablet per day
Study: 703670
Drug: (+)-Cyanidanol-3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-Cyanidanol-3 at a dosage of 2 X 3 or 3 X 2 tablets per day
Study: 703670
Drug: (+)-Cyanidanol-3 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+)-Cyanidanol-3 at all dose levels
Study: 31775729
Drug: DQTM tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DQTM tablet (Dan Qi Tong Mai tablet) at single doses of up to 5760 mg
Study: 31775729
Drug: DQTM tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DQTM tablet (Dan Qi Tong Mai tablet) at twice-daily doses of up to 2160 mg for 14 consecutive days
Study: 31775729
Drug: DQTM tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DQTM tablet
Study: 26522871
Drug: Supervised aerobic
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised aerobic exercise (45-50 min/week three times a week for four months) plus pharmacotherapy
Study: 26522871
Drug: Only antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only antidepressant medication
Study: 20948512
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and pharmacologic treatment
Study: 20439549
Drug: Supplements containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements containing greater than 50% DHA
Study: 17335293
Drug: Nonsurgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical therapy with chemoradiotherapy
Study: 2186058
Drug: MK-329 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-329 (10 mg)
Study: 7194062
Drug: etofylline clofibrate
Normalized name: etofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: etofylline clofibrate 500 mg daily (2 x 1 capsule)
Study: 7194062
Drug: etofylline clofibrate
Normalized name: etofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: etofylline clofibrate 750 mg daily (3 x 1 capsule)
Study: 30691405
Drug: Multicomponent physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent physical activity program (MEFAP) with twelve 1.5 h-weekly sessions
Study: 28323916
Drug: Hydrocortisone infusion
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusion (0.2 mg/kg/min for 14 hours)
Study: 16808927
Drug: 480 mg
Normalized name: magaldrate 480 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg EGb 761
Study: 16808927
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg EGb 761
Study: 11820148
Drug: Orlistat treatment
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat treatment with diet
Study: 11570304
Drug: thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: thrombolytic therapy
Study: 31754793
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with pazopanib (800 mg daily for 1 week) and paclitaxel (80 mg/m2 weekly for 18 weeks) followed by maintenance pazopanib
Study: 31754793
Drug: Single-agent pazopanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent pazopanib
Study: 23645158
Drug: MgSO4 infusion
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 infusion (15 mg/kg/h)
Study: 17523581
Drug: Single KPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single KPT group (two addiction counseling sessions with no additional ketamine therapy)
Study: 15448531
Drug: Basal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal group (12-ml/h basal rate, 0.05-ml patient-controlled bolus dose)
Study: 15448531
Drug: Basal-bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus group (8-ml/h basal rate, 4-ml bolus dose)
Study: 15448531
Drug: Bolus group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus group (0.3-ml/h basal rate, 9.9-ml bolus dose)
Study: 333862
Drug: Biphasic hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic hormone combination (Cyclacur) with 2 mg estradiol valerianate for 11 days, followed by 2 mg estradiol valerianate plus 0.5 mg dl‐norgestrel for 10 days, and a 7-day medication-free period.
Study: 27353750
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable hydrogel contact lenses worn by CLIDE
Study: 27353750
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable hydrogel contact lenses worn by NO-CLIDE
Study: 26032239
Drug: Other Chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Chemotherapeutic Agents
Study: 23377328
Drug: Topical product
Normalized name: Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical product containing 0.5% ellagic acid and 0.1% salicylic acid
Study: 21187200
Drug: verum treatment
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: verum treatment (acupoint ST-34 stimulation)
Study: 21187200
Drug: control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: control treatment (nonacupoint stimulation)
Study: 19133707
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 microg/kg plus 2% prilocaine 3 mg/kg
Study: 19133707
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg plus 2% prilocaine 3 mg/kg
Study: 19133707
Drug: 2% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% prilocaine 3 mg/kg
Study: 21244548
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 20 mg/kg/day
Study: 21244548
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 5 mg/kg/day
Study: 2729944
Drug: Cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole sodium (0.375 g)
Study: 2729944
Drug: Cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole sodium (0.750 g)
Study: 2729944
Drug: Cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole sodium (1 g)
Study: 2729944
Drug: Cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole sodium (2 g)
Study: 2729944
Drug: Cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole sodium (0.375 g to 2 g)
Study: 30976787
Drug: Uninterrupted edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted edoxaban 60 mg (30 mg for dose reduction)
Study: 29273578
Drug: Dasiglucagon 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.1 mg
Study: 29273578
Drug: Dasiglucagon 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 0.3 mg
Study: 29273578
Drug: Dasiglucagon 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasiglucagon 1.0 mg
Study: 29273578
Drug: GlucaGen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlucaGen 0.5 mg
Study: 29273578
Drug: GlucaGen 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlucaGen 1.0 mg
Study: 11136281
Drug: OFA (omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFA (omeprazole, furazolidone, amoxicillin)
Study: 7527421
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) administered at the same time as buserelin-HMG
Study: 7527421
Drug: No growth
Normalized name: Mechano growth factor
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No growth hormone (GH) administered
Study: 2537003
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum treatment
Study: 2537003
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum treatment (after switching from placebo)
Study: 27710596
Drug: Quercetin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (500 mg/day)
Study: 30646929
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA treatment for 4-12 weeks
Study: 30646929
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 4-12 weeks
Study: 28556584
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of prednisone (0.8-1.0 mg/kg/day)
Study: 28556584
Drug: Medium doses
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium doses of prednisone (0.5-0.6 mg/kg/day)
Study: 23312689
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of levothyroxine (group 1)
Study: 23312689
Drug: Tablet formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation of levothyroxine (group 2)
Study: 20080830
Drug: Palonosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.25 mg) + Dexamethasone (8 mg) on day 1
Study: 20080830
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg b.i.d.) on days 2 and 3
Study: 18389745
Drug: lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lactated Ringer's solution alone (Group B, n=16)
Study: 18389745
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline and Ringer's solution, 1:1 ratio (Group C, n=15)
Study: 11022927
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy (n=76)
Study: 11022927
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (control group, n=74)
Study: 8792046
Drug: Tension night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tension night splint (TNS) in addition to standard treatment (anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Study: 8792046
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment: anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Study: 3736637
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hyperprolactinemia
Study: 29519882
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (after transfer of 25 participants)
Study: 25230304
Drug: Intracoronary anisodamine
Normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary anisodamine (1 mg/5 ml) and diltiazem (2 mg/5 ml)
Study: 25230304
Drug: Saline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (5 ml) and diltiazem (2 mg/5 ml)
Study: 18841263
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/day to 8 mg/day)
Study: 18841263
Drug: metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (500 mg/day to 2000 mg/day)
Study: 18841263
Drug: glyburide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide (5 mg/day to 20 mg/day)
Study: 15932703
Drug: Tongxinluo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo capsule
Study: 11834429
Drug: Fasting with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting with GH receptor blockade (pegvisomant)
Study: 11834429
Drug: Fasting without
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting without GH receptor blockade
Study: 10612300
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (5 mcg every 2 weeks for 8 doses, plus 1 i.m. dose at month 12)
Study: 10612300
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (20 mcg for 4 doses at months 0, 1, 2, and 12)
Study: 7821102
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg erythromycin
Study: 31289971
Drug: Tooth whitening
Normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Tooth Whitening Strip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth whitening with a photo-activated whitening gel
Study: 31744060
Drug: Eggplant powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eggplant powder (1.2 g/day; 2.3 mg of ACh/day) for 12 weeks
Study: 25543296
Drug: c-PACT (curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: c-PACT (curcumin at 1.5 mg.mL(‐1) with blue LED light)
Study: 23112214
Drug: Balanced starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced starch (HES, 130/0.4, 6%) solution
Study: 20209995
Drug: Balanced crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution
Study: 20924633
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of G-CSF (lenograstim, 100 μg)
Study: 20924633
Drug: G-CSF (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (100 μg) administered every other day
Study: 19183141
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of paroxetine (Paxil)
Study: 16813531
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg/day, orally)
Study: 2008949
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg midazolam
Study: 1763599
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg fentanyl
Study: 8487239
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with MPA 5.0 mg for 12 days of each 25-day cycle plus CEE 0.625 mg daily
Study: 8487239
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with MPA 2.5 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Study: 8487239
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with MPA 5.0 mg daily for 12 treatment cycles plus CEE 0.625 mg daily